Form 4: Neumora Therapeutics CFO Joshua Pinto Sells Shares Under 10b5-1 Trading Plan

Neumora Therapeutics' CFO, Joshua Pinto, executed multiple sales of common stock between August 22 and August 26, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Joshua Pinto, the Chief Financial Officer of Neumora Therapeutics, sold shares of the company's common stock.
• The sales occurred on August 22, August 23, and August 26, 2024.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan.
• On August 22, 28,496 shares were sold at a weighted average price of $11.6321.
• On August 23, 24,169 shares were sold at a weighted average price of $11.5853.
• On August 26, 31,642 shares were sold at a weighted average price of $11.7751.
• Following these transactions, Pinto directly owns 85,000 shares and indirectly owns 154,658 shares through Maple DE Holdings LLC.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document simply reports stock sales under a pre-arranged trading plan, which is a common practice.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, potentially impacting the stock price, although sales under a 10b5-1 plan are typically less concerning.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies. The use of 10b5-1 trading plans allows insiders to sell shares over a predetermined period, mitigating concerns about insider trading. Investors often monitor these transactions for insights into management's perspective on the company's valuation and future prospects.

Comparison to Industry Standards

• Executive stock sales are a routine part of corporate governance, and the use of 10b5-1 plans is a standard practice.
• Comparable companies like Biogen, Eli Lilly, and Pfizer also see regular Form 4 filings related to executive stock transactions.
• The size and frequency of these sales are generally in line with industry norms for companies of Neumora's size and stage.

Stakeholder Impact

• The stock sales could have a minor impact on shareholder sentiment, but the existence of a 10b5-1 plan should mitigate concerns.
• There is no direct impact on employees, customers, suppliers, or creditors.

Key Dates